1Frei E 3rd,Canellos GP.Dose:a critical factor in cancer chemotherapy.Am J Med,1980,69:585-594.
2Norton L,Simon R,Tumor size,sensitivity to therapy,and design of treatment schedules.Cancer Treat Rep,1977,61:1307-1317.
3Hudis C.New approaches to adjuvant chemotherapy for breast cancer.Pharmacotherapy,1996,16(3 Pt 2):88S-93S.
4Norton L. Evolving concepts in the systemic drug therapy of breastcancer. Semin Oncol, 1997, 24 (4suppl 10): S3-10.
5Altundag K, Altundag O, Elkiran ET, et al. Addition of granulocytecolony stimulating factor (G-CSF) to adjuvant treatment may increase survival in patients with operable breast cancer: interaction of G-CSF with dormant micrometastatic breast cancer cells. Med Hypotheses, 2004, 63: 56-58.
6Epstein RJ. The CXCL12-CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies. Nat Rev Cancer, 2004, 4: 901-909.
7Citron ML, Berry DA, Cirrincione C. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol, 2003, 21:1431-1439.
8Venturini M, Aitini E, Del Mastro L,et al. Phase Ⅲ adjuvant trial comparing standard versus accelerated FEC regimen in early breast cancer patients with poor prognostic factors:5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol,2001, 19: 602-611.
9Fomier MN, Seidman AD, Lake D, et al. Increased dose-density(DD) is feasible: a pilot study of epirubicin and cyclophosphamide(EC) followed by paclitaxel (T), at 10-11 day interval with filgrastim support, for women with early breast carcinoma (BC).ASCO proceeding 2005. 616.
10Del Mastro L, Bruzzi P, Nicolo G. HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients. Br J Cancer, 2005, 93: 7-14.
3Paridaens R, Biganzoli L, Bnming P, et al. Paclitaxel versus Doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer:a European organization for research and treatment of cancer randomized study with cruss-over. J Clin Oncol, 2000, 18:724-733.
4Henderson C, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubin dose in an adjuvant chemotherapy regimen for patients with nodepositive primary breast cancer. J Clin Oncol, 2003, 21:976-983.
5Memorial Sloan-Kettering Cancer Center. The use of taxanes in early breast cancer. EJC Supplements, 2003, 1:1-10.
6Norton L, Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep, 1977, 61:1307-1317.
7Norton L. Evolving concepts in the systemic drug therapy of breast cancer. Semin Oncol, 1997, 24(4 suppl 10) :3-10.
8Altundag K, Altundag O, Elkiran ET, et at. Addition of granulocyteconoly stimulating factor (G-CSF) to adjuvant treatment may increase survival in patients with operable breast cancer: interaction of G-CSF with dormant micrometastatic breast cancer cells. Med Hypotheses, 2004, 63:56-58.
9Epstein RJ. The CXCL12-CXCR4 ehemotaetie pathway as a target of adjuvant breast cancer therapies. Nat Rev Cancer, 2004, 4: 901-909.
10Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol, 2003,21:1431-1439.
